Evonile Pharma Limited moves to reshape its capital structure

The effective discount and dilution cannot be confirmed from the cited filing. The 4 November 2026 board approval only authorizes a rights issue of up to ₹900 Cr and states that the record date, issue price and entitlement ratio would be decided by the Rights Issue Committee. ^[1]

• Effective discount: Not confirmed. It requires the Letter of Offer’s issue price and the market price on the record date.

Formula: `discount = 1 − (rights issue price / record-date market price)`.

• Dilution impact: Not confirmed. It requires the existing number of equity shares and the number of rights shares offered. The reported equity share capital of ₹12.34 Cr is a capital amount, not a share count, and the face value is not stated. ^[2]
• For non-participating shareholders: If the entitlement is `1 share for every X existing shares`, dilution would be `1 / (X + 1)` of the post-issue equity base, assuming full subscription.
• For shareholders who fully subscribe: Their percentage ownership is generally maintained, subject to the final rights structure and any unsubscribed or renounced portion.

The ₹900 Cr issue size alone is insufficient to calculate either the discount or dilution because the issue price, record-date market price and entitlement ratio are required.

The specific split of net proceeds between debt repayment and working capital could not be confirmed from the cited financial evidence. The latest audited FY26 figures report total debt of ₹0.00 Cr and total equity of ₹817.83 Cr on a standalone basis; the reported debt-to-equity ratio was therefore 0.00x. ^{[3] [4] [5]}

Debt-to-equity impact

Let:

• `P` = net equity proceeds
• `D` = portion earmarked for debt repayment
• `W` = portion earmarked for working capital
• `D + W = P`

If the infusion is an equity issue and no new borrowings are raised:

• Post-issue equity = ₹817.83 Cr + `P`
• Post-repayment debt = ₹0.00 Cr − `D`, floored at zero
• Post-issue debt-to-equity ratio = `max(0, ₹0.00 Cr − D) / (₹817.83 Cr + P)`

Because the latest audited balance sheet already reports no debt, the debt-repayment allocation cannot reduce the ratio below 0.00x. Accordingly, the ratio would remain approximately 0.00x, provided the proceeds are equity capital and the company does not add new debt. The working-capital allocation would increase liquidity but would not itself change debt-to-equity unless it is funded through borrowings.

The exact rupee allocation between debt repayment and working capital, and the net-proceeds amount `P` needed to calculate the post-issue equity balance, could not be confirmed for the relevant offer.

The ₹900 Cr rights issue is vastly larger than the company’s recent reported capex. FY26 capex was only ₹0.34 Cr, so the issue is approximately 2,647x FY26 capex and exceeds it by ₹899.66 Cr, based on a standalone comparison. The company reported zero capex in FY24 and FY25. ^{[1] [6] [7] [8]}

This means the fundraise cannot be explained by the recent capex run-rate alone. It appears sized for broader strategic or balance-sheet purposes, but the cited rights-issue approval does not provide a project-wise deployment split; it only states that the issue proceeds will be used under a utilization plan to be finalized by the company. ^[1]

Promoter participation cannot yet be matched against historical equity-raise behaviour. The promoter group held 70.68% of the company in the latest shareholding data, but the rights-issue approval cited here does not disclose a binding promoter subscription commitment, minimum underwriting, or an intention to subscribe in proportion to its entitlement. The issue price, entitlement ratio and record date were also left for subsequent determination. ^[1]

The available ownership trail shows promoter holding unchanged at 70.68% across the reported quarters, but that is not evidence of participation in earlier equity raises. Historical subscription records for previous equity issues, and a quantified commitment for this issue, could not be confirmed from the cited sources. Accordingly, alignment with past participation is presently untestable, rather than demonstrably positive or negative.